Letters
Multicentre trial should be welcomed
EDITOR,--R D Bulbrook's concern about the multicentre adjuvant tamoxifen trial1 is misplaced. This trial seeks to address the vexed question of the optimum duration of adjuvant treatment with tamoxifen. The trial randomises patients who have been taking adjuvant tamoxifen for at least two years either to stop at this point or to continue for a further three years. There is no question of the trial embracing very long periods of treatment such as the 10 years referred to in Bulbrook's editorial. It is regrettable that this editorial may discourage recruitment to this extremely useful and pragmatic trial.Consultant surgeon Hereford Hospitals NHS Trust, County Hospital, Hereford HR1 2ER
A P Corder
- Bulbrook RD. Long term adjuvant therapy for primary breast cancer. BMJ 1996;312:389-90. (17 February.)
[Free Full Text]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
StumbleUpon 
Technorati What's this?
Relevant Article
- Long term adjuvant therapy for primary breast cancer
- R D Bulbrook
BMJ 1996 312: 389-390.[Extract] [Full Text]
This Article
- Full text
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Find similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Related Content
-
Immunology (including allergy)
- Breast cancer
- Relevant Article
- Find this article in its weekly table of contents
Bookmark with
What's new
Latest blogs
Find BMJ on:
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article. Print issues
